ABSTRACT
INTRODUCTION
IL-15 is a pleiotropic cytokine that has been shown to induce and regulate a wide range of immune functions [1, 2] . Specifically, IL-15 is critical for lymphoid development and peripheral maintenance of innate immune cells and immunological memory of T cells, in particular natural killer (NK) and CD8 + T cell populations [1, 2] . However, while IL-15 does not promote the maintenance of CD4 + CD25 + FOXP3 + regulatory T cells (Tregs), IL-2 has been demonstrated to induce their development [3] [4] [5] . Furthermore, IL-15 has been shown to protect effector T cells from IL-2-mediated activation-induced cell death (AICD) [6, 7] . For these reasons, IL-15 has long been speculated to have high therapeutic potential for longterm anti-tumor immunity. The cytokine's immune effect in cancer patients has been recently examined. In a firstin-human clinical trial of recombinant human (rh)IL-15, Conlon et al. found that rhIL-15 administration induced a 10-fold expansion of NK cells and significantly increased the proliferation of γδT cells and CD8 + T cells [8] . Despite its promising anti-tumor immune capacity, IL-15 has been shown to exhibit a short half-life and high doses were required to achieve biological responses in vivo [9, 10] , hence resulting in clinical toxicities and limited anti-tumor responses in patients [8] . To increase the therapeutic effectiveness and facilitate the use of IL-15 in the immunotherapy of cancer and chronic infection, an IL-15 N72D superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) has been developed to address some of the limitations of IL-15-based therapeutics. First, in the IL-15 N72D superagonist (IL-15SA), the asparagine 72 was replaced with the aspartic acid residue, providing improved affinity for CD122-expressing immune cells and promoting stronger cytoplasmic signals for activation and proliferation of NK and CD8
+ T cells at lower dosages [11] . Furthermore, it has been previously shown that the biological activity of IL-15 increased when IL-15 was pre-complexed with IL-15Rα [12, 13] . Simulating trans-presentation between dendritic cells/macrophages and effector cells, the sushi domain of IL-15Rα, fused to the Fc portion of human IgG1 [11] , has been engineered to incorporate the trans-presentation mechanism, consequently increasing the half-life and in vivo biological activity of the IL-15-SA [11, 14] . Overall, when compared with native IL-15, the IL-15SA/IL-15RαSu-Fc fusion complex has been shown to exhibit a longer serum half-life and retention in lymphoid organs and increased in vivo biological activity by 5-25-fold [11, 14, 15] .
Due to its potent immunostimulatory capability, the IL-15SA/IL-15RαSu-Fc fusion complex has been shown to be efficacious in several experimental animal models of cancer, namely murine multiple myeloma [16] , rat bladder cancer [17] , and murine glioblastoma [18] , and currently is being tested against human hematological and solid cancers in multiple clinical trials (ClinicalTrials.gov). Here, we evaluated for the first time, (1) the immunomodulatory effect of IL-15SA/ IL-15RαSu-Fc on the subpopulations of NK cells (and memory CD8 + T cells) and (2) its anti-tumor activity against pulmonary metastases in the 4T1 breast and CT26 colon carcinoma models, with the aim of providing a rationale for the utilization of IL-15SA/IL-15RαSu-Fc, especially in combination with checkpoint inhibitors, in the immunotherapy of highly metastatic cancers.
RESULTS

IL-15SA/IL-15RαSu-Fc induced marked elevations of TH 1 and TH 2 cytokines
Due to the pleiotropic nature of IL-15 in regulating various immune responses, we first sought to examine the extent to which IL-15SA/IL15-RαSu-Fc promoted the production of Th1 and Th2 cytokines over a 7-day period. Mice administered with IL-15SA/IL15RαSu-Fc exhibited a transient increase in the serum concentration levels of IFN-γ, TNF-α, IL-5, and IL-10 ( Figure 1A ). Serum IFN-γ level, in particular, peaked on day 1 (p = 0.004), followed by IL-5 and IL-10 on day 2 (p = 0.005 and p = 0.030, respectively), then TNF-α on day 3 (p = 0.001) ( Figure  1A ). There was no significant change observed in serum IL-6 level ( Figure 1A ; inset). The greatest fold change was observed for IFN-γ, whose fold increase was as high as ~11-fold (p = 0.004) on day 1, whereas the other cytokines did not increase beyond 5-fold during the 7-day period ( Figure 1B) . The duration of elevated serum cytokine level was the greatest for TNF-α, maintaining significantly above the baseline on day 7 (p = 0.001), and the shortest for IFN-γ, lasting up to day 4 (p = 0.028) ( Figure 1A ). Even though administration of IL-15SA/IL-15RαSu-Fc to mice rapidly increased inflammatory cytokines at the dose described, no observable toxicities were seen in mice throughout the 7-day period.
IL-15SA/IL-15RαSu-Fc promoted the expansion of NK, T, B cell and granulocytic populations in the spleen
Next, we examined the effect of IL-15SA/ IL15RαSu-Fc on major immune populations in the spleen. Administration of IL-15SA/IL-15RαSu-Fc to mice induced the greatest effect on NK cells, whose increase in the total number was highest on day 3 (p = 0.003) and lasted markedly above the baseline up to day 5 (p < 0.001). T and B cells were similarly affected, as the total numbers of CD8 + and conventional (conv.) CD4 (Figure 2A ). Among these lymphocytes, the highest fold change was observed in NK cells (~13 fold on day 3; p = 0.003) followed by CD8 + T cells (~3 fold on day 3; p = 0.007) then CD4 + (conv. and Tregs) T and B cells. We also examined the effect of IL-15SA/IL-15RαSu-Fc on granulocytic and monocytic populations. The total number of CD11b + Ly-6C int Ly-6G + cells, identified as either neutrophils or granulocytic myeloid derived suppressor cells (MDSCs), increased as high as 6-fold on day 2 (p = 0.002), whereas CD11b + Ly-6C
hi Ly-6G − cells, characterized either as monocytes or monocytic-MDSCs, appeared to be unaffected by IL-15SA/IL-15RαSu-Fc. IL-15SA/IL-15RαSu-Fc similarly enhanced the expansion of NK cells in PBMCs in comparison with those in the spleens (Supplemental Figure 1) . Taken together these data are consistent with the overall immunomodulatory property of IL-15, which activates both the innate and adaptive arms of the immune system [2, 19] .
IL-15SA/IL-15RαSu-Fc most affected IL-15-responding memory T cells, specifically of the innate phenotype in the CD8 + T cell compartment
We observed that even though the total numbers of both CD8 + and CD4 + T cells increased, partly as a result of overall increase in the total number of splenocytes, the fold increase was greater in CD8 + than in CD4 + T cells or splenocytes ( Figure 2B ). We therefore investigated which splenic T cell subsets, in particular in the CD8 + compartment, responded to IL-15SA/IL15RαSu-Fc treatment. More specifically, we sought to examine the following phenotypically defined T cell subsets: (1) Figure 3B ) whose immune response profile was very similar to that of NK cells (Figures 2 and 3) . Within IL-15 memory CD8 + T cell responders, those of the innate phenotype (NKG2D + PD1 -) increased dramatically as high as ~70 fold on day 3 (p = 0.012) ( Figure 3B ), also having response kinetics similar to that seen in NK cells. However, IL-15SA/IL-15RαSu-Fc did not have a similar magnitude of effect on these subsets in the CD4 + T cell compartment ( Figure 3A) . Finally, in both CD8 + and CD4 + T cell compartments, IL-15SA/IL-15RαSu-Fc had an effect on IL-15 memory responders with the adaptive phenotype (NKG2D − PD1 + ), but not to the same degree of magnitude as those with the innate phenotype ( Figure  3B ). These data are in line with IL-15SA/IL-15RαSu-Fc's capacity to convert antigen-experienced memory CD8 + T cells into non-antigen-specific innate effector cells as demonstrated by Xu et al. [16] . responded to IL-15SA/IL-15RαSu-Fc treatment. We found that unlike CD8 + T cells, nearly all NK cells throughout the 7-day period of IL-15SA/IL-15RαSu-Fcmediated immune response had an activated phenotype (CD122 + NKp46 + ), leading us to further phenotype the NK population using CD11b and CD27 surface markers [20] . It has been reported that CD11b + CD27 hi NK cells were resistant to self-major histocompatibility complex (MHC) class I-induced tolerance and exhibited high cytotoxicity, cytokine production and migratory capacity [20] [21] [22] [23] , hence termed "high effector" NK cells. On the other hand, CD11b + CD27 lo or "terminal effector" NKs, albeit having high cytotolytic activity, produced low levels of cytokines, were less migratory, and highly expressed the terminal differentiation marker KLRG-1 [20] [21] [22] [23] . The results showed that IL-15SA/IL-15RαSu-Fc significantly increased the total numbers of both high (CD11b + CD27 hi ) and terminal (CD11b + CD27 lo ) effector NK cells, peaking on day 3 (high effectors: p = 0.001; terminal effectors: p = 0.008) ( Figure 4A ), and the highest fold increase was observed in high effector NK cells (up to ~20 fold on day 3; p = 0.001; Figure 4B ). The capacity of IL-15SA/IL-15RαSu-Fc to generate high effector NK cells suggests that per-cell NK function may be increased as a result of the cytokine complex treatment.
IL-15-
IL-15SA/IL-15RαSu-Fc increased total NK cells and function on a per-cell basis
Because IL-15SA/IL-15RαSu-Fc expanded high effector NK cells, we next investigated the effect of IL-15SA/IL-15RαSu-Fc on total and per-cell function of NK cells. On day 3, the proportion of high effector NK cells increased (~2-fold on day 3), resulting in decreased proportions of other NK subsets ( Figure 5A ). When we examined the total NK activity using day 3 splenocytes as effectors and YAC-1 cells as targets, IL-15SA/IL- 15RαSu-Fc dramatically increased total NK-mediated cytotoxicity (E:T/100:1, p = 0.004) ( Figure 5B), which was consistent with the increased percentage of splenic NK cells from the IL-15SA/IL-15RαSu-Fc treatment group (~4-fold on day 3; Figure 4A ). We then purified NK cells from the spleens (purity: ~85%) on day 3 to determine the effect of IL-15SA/IL-15RαSu-Fc on NK cells on a per-cell basis ( Figure 5C ). The results indicated that IL-15SA/IL-15RαSu-Fc significantly enhanced the per-cell function of NK cells (E:T/100:1, p< 0.001), mediated in large part by the presence of NKG2D, as the per-cell NK-mediated lytic activity (IL-15SA/IL15RαSu-Fc: 50 LU vs. Isotype Ctrl: 5 LU) decreased when a blocking NKG2D antibody was used ( Figure  5D ). These studies indicate that IL-15SA/IL-15RαSu-Fc has the potential to induce a potent NK-mediated antitumor response due to its ability to enhance not only total NK function but also per-cell NK function through the generation of high effector NKs.
We next conducted studies in tumor-bearing mice to determine if treatment with IL-15SA/IL-15RαSu-Fc would impact immune cell populations to a similar degree as observed in non-tumor-bearing mice. We utilized the spontaneous metastasis model of 4T1 breast carcinoma. We injected 1 µg of IL-15SA/IL-15RαSu-Fc on day 7 post-tumor implantation when the primary tumor size ranged between 50-100 mm 3 and harvested splenocytes 3 days later (3 day post ALT-803 administration/day10 post tumor implantation. Primary tumor volumes on day 10 post tumor challenge were ~100 mm 3 for both In radioactivity was measured to determine cytotoxic function. C. Purified splenic NK cells were used as effectors in the cytotoxicity assay described in (B). D. Anti-mouse NKG2D mAb or its isotype control were added in the cytotoxicity assay described in (C); NK activity in lytic units (LU). All experiments were performed twice with similar results. Error bars represent SE of mean of quadruplicate measurements. *p < 0.05, statistical significance. This experiment was repeated 2 times with similar results. www.impactjournals.com/oncotarget ALT-803 and PBS treatment groups. As in non-tumor bearing mice, administration of IL-15SA/IL-15RαSu-Fc to mice induced the greatest effect on NK cells (3.5 fold, p < 0.001), followed by a significant increase in CD8 + and CD4 + T-cells ( Figure 6A and 6B). Tregs were not significantly increased. When total NK activity was analyzed using day 3 splenocytes as effectors and 4T1 tumor cells as targets, IL-15SA/IL-15RαSu-Fc dramatically increased total NK-mediated cytotoxicity ( Figure 6C ), (E:T/100:1, p <0.001). Similar results were observed using enriched NK cells from the spleens of IL-15SA/IL-15RαSu-Fc treated tumor-bearing mice. These studies indicate that IL-15SA/IL-15RαSu-Fc has the potential to induce a potent NK-mediated anti-tumor response due to its ability to enhance total NK function in tumor-bearing mice.
IL-15SA/IL-15RαSu-Fc showed significant antimetastatic activity, dependent on CD8 + T cells as well as NK cells, and prolonged survival in 4T1 breast tumor model
To assess the functional consequences of IL-15SA/ IL-15RαSu-Fc-mediated anti-tumor immunity and efficacy, we used the spontaneous metastasis model of 4T1 breast carcinoma, as the progressive invasion of 4T1 tumor cells to draining lymph nodes and other organs is similar to that seen in the advanced breast cancer in humans [24, 25] . We injected 1 µg of IL-15SA/IL-15RαSu-Fc on day 7 post-tumor implantation when the primary tumor size ranged between 50-100 mm 3 . IL-15SA/IL-15RαSu-Fc did not affect the primary tumor growth, but generated significant anti-metastatic activity, as the number of 4T1 In radioactivity was measured to determine cytotoxic function. metastases in the lung from IL-15SA/IL-15RαSu-Fctreated mice decreased significantly (p < 0.001) ( Figure  7A ). Since primary tumors are surgically removed in patients with metastatic breast tumors, we modeled this scenario by performing surgical resection of the 4T1 primary tumor on day 14 and measured survival rates thereafter. Mice treated with IL-15SA/IL-15RαSu-Fc exhibited a significantly higher survival rate (p = 0.001), hence greater median overall survival (50 days) than that of the control group (38 days) ( Figure 7B . *p < 0.05, statistical significance determined by the two-tailed Mann-Whitney U test. B. For the survival study, 4T1 tumor implantation and IL-15SA/IL15RαSu-Fc or PBS administration were performed as in (A). Primary tumors were excised on day 14 post 4T1 implantation, then the survival rates of IL-15SA/IL-15RαSu-Fc-treated (n = 6) and PBS-treated (n = 9) mice were examined. Median overall survival (mOS) for each group is shown. *p < 0.05, statistical significance determined by the Gehan-Breslow-Wilcoxon test. For C. T cell and D. NK cell depletions, 4T1 tumor implantation and IL-15SA/IL-15RαSu-Fc (ALT-803) or PBS administration were performed as in (A). Anti-CD8 (Clone 2.43) and anti-CD4 (GK 1.5) mAbs were used to deplete CD8 + and CD4 + T cells, respectively. Anti-asialo-GM1 Ab was used to deplete NK cells. Clonogenic metastatic analysis was performed as in (A). Also shown in (D) is the percentage of mice for each treatment group that had less than 300 metastases. Error bars represent SE of mean of number of clonogenic metastasis per group. *p < 0.05, statistical significance determined by the two-tailed Mann-Whitney U test. NS: no significance determined by the two-tailed Mann-Whitney U test.
Fc-treated mice ( Figure 7D ). The role of NK cells was most evident in the proportion of mice that had less than 300 metastases ( Figure 7D , untreated mice vs. NK depleted IL-15SA/IL-15RαSu-Fc-treated mice, p =0.09). These data are consistent with the published in vivo data pertaining to IL-15SA/IL15RαSu-Fc, which have shown that its mediation of anti-tumor and viral responses is dependent on CD8 + T and/or NK cells [16] [17] [18] 26] . Furthermore, these data correlate with the kinetic analysis of IL-15SA/IL-15RαSu-Fc-induced immune responses shown earlier, as NK and CD8 + T cell populations were most expanded by IL-15SA/IL-15RαSu-Fc administration (Figure 2 ).
IL-15SA/IL-15RαSu-Fc therapy, particularly in conjunction with anti-CTLA-4 treatment, resulted in increased survival against experimental pulmonary metastasis of CT26 colon carcinoma cells
We tested the anti-tumor efficacy of IL-15SA/ IL-15RαSu-Fc in an additional experimental metastasis tumor model using CT26 colon carcinoma cells. In a sideby-side survival study with rIL-15, we have shown that IL-15SA/IL-15RαSu-Fc generated a significantly higher anti-tumor activity than rIL-15 and prolonged survival against CT26 pulmonary metastasis [15] . In this study, we then examined the combination potential of IL-15SA/IL15RαSu-Fc with the checkpoint inhibitors anti-CTLA-4 and anti-PD-L1. CT26 cells, similar to 4T1, have a very low level of PD-L1, but unlike 4T1, they highly express the CTLA-4 ligand, B7-1, on the surface [27] [28] [29] . To validate these findings, CT26 cells were stained with fluorochrome-labeled antibodies specific for PD-L1 and CTLA-4, followed by a flow cytometry analysis, which confirmed the poor expression of PD-L1 (2.24%) but significant expression of B7-1 (30.5%) on CT26 tumor cells ( Figure 8A ). In addition, we examined PD-L1 and B7-1 expressions on 4T1 and CT26 in-vitro and found that PD-L1, but not B7-1, expression was elevated in these cells after IFNγ treatment (Supplemental Figure 2) . The results revealed that IL-15SA/IL-15RαSu-Fc when administered in combination with anti-CTLA-4, but not anti-PD-L1, synergistically increased survival of CT26-bearing mice (p < 0.01), ( Figure 8B ). Finally, we wanted to determine whether anti-PD-L1, albeit ineffective in combination with IL-15SA/IL-15RαSu-Fc ( Figure 8B ), provided survival benefit when incorporated into the combination treatment of IL-15SA/IL-15RαSu-Fc and anti-CTLA-4. The addition of anti-PD-L1 trended to improve the IL-15SA/IL-15RαSu-Fc plus anti-CTLA-4 treatment in the survival of CT26-bearing mice ( Figure  8C ). The same triple combination strategy, using rIL-15, was less effective than even IL-15SA/IL-15RαSu-Fc treatment alone ( Figure 8C ). Overall, administration of IL-15SA/IL-15RαSu-Fc exhibited a potent antimetastatic activity against not only 4T1 breast (Figure 7 ) but also CT26 colon carcinoma (Figure 8 ), and produced a synergistic anti-tumor response against CT26 pulmonary metastasis in combination with checkpoint inhibitors, driven mainly by anti-CTLA-4.
DISCUSSION
To our knowledge, the results shown here report for the first time that IL-15SA/IL-15RαSu-Fc significantly promoted the development of "high effector" NK cells (Figure 4) , which increased not only total function but also per-cell function of NK cells ( Figure 5 ). In addition, IL-15SA/IL-15RαSu-Fc induced high levels of inflammatory cytokines, particularly IFN-γ (Figure 1) , and promoted the development of innate memory CD8 + T cells expressing NKG2D ( Figure 3) ; the latter immune response is a unique property of IL-15SA/IL-15RαSu-Fc that rIL-15 does not possess [14, 16] . We also demonstrate for the first time that IL-15SA/IL-15RαSu-Fc exhibited potent anti-metastatic activity, dependent on CD8 + T and NK cells, and prolonged the survival of mice, initially in the 4T1 breast tumor model, which resembles advanced breast cancer in humans ( Figure 7 ). This anti-metastatic property of IL-15SA/IL-15RαSu-Fc was again exhibited in a second tumor metastasis model, involving CT26 colon carcinoma cells, with which we showed for the first time that the metastatic inhibition by IL-15SA/IL-15RαSu-Fc was more potent than that of rIL-15 ( Figure 8A ) and could be synergized with checkpoint inhibitors ( Figure  8B and 8C) . The studies reported here further define mechanistically the prior immune and anti-tumor studies of IL-15SA/IL-15RαSu-Fc [16] [17] [18] .
Acute clinical toxicities have been a major concern for native rIL-15 administration due to highly elevated levels of pro-and anti-inflammatory cytokines such as IFN-γ, IL-6, TNF-α, and IL-10 [8] . In our murine model using a single intraperitoneal (i.p.) injection of 1 µg IL-15SA/IL-15RαSu-Fc, we also observed significant elevations of IFN-γ, TNF-α, and IL-10 ( Figure 1A ), but not IL-6 ( Figure 1A ; inset), which interestingly showed the greatest fold increase in the phase I clinical study of rhIL-15 [8] and was determined to be a primary cytokine mediator of toxicity in leukemia patients treated with chimeric antigen receptor effector cells [30, 31] . In our preclinical study, a single i.p. administration of 1 µg IL-15SA/IL-15RαSu-Fc significantly increased levels of inflammatory cytokines, but mice showed no observable toxicities at this dose (as determined by clinical observation and animal weights), possibly due to no significant change in serum IL-6 level ( Figure  1A ; inset). Our data reported here using Balb/c mice are consistent with data recently reported of an extensive non-clinical toxicity and pharmacodynamic studies of IL-15SA/IL-15RαSu-Fc in C57BL/6 mice and non-human primates [15] . Several phase I clinical studies have now been initiated with IL-15SA/IL-15RαSu-Fc that will also examine the levels of induced Th1 and Th2 cytokines.
Besides its increased potency and longer halflife compared with native IL-15 [11] , IL-15SA/IL15RαSu-Fc was shown to induce innate memory CD8 + T cells capable of non-antigen-specific killing in murine myeloma models [14, 16] . Our results are consistent with the published findings [14, 16] cell compartment, in particular those having the innate (NKG2D + ) phenotype (Figure 3) . Notably, the kinetic profile of innate IL-15 memory responders in the CD8 + T cell population was very similar to that of NK cells (Figures 2 and 3) , confirming the notion that IL-15SA/ IL-15RαSu-Fc prevalently activates the innate arm of the immune response.
The subsets of CD8 + T cells such as IL-15 memory responders have been extensively described phenotypically and functionally [32] [33] [34] [35] [36] [37] . However, significantly less analysis has been carried out on subpopulations of NK cells, which, unlike T cells, are classically considered non-antigen-specific and have no well-defined memory development [38, 39] . Because murine NK cells when exposed to IL-15SA/IL-15RαSu-Fc in vivo responded the highest among major immune cells in terms of total number and fold increase (Figure 2) , it became a prerequisite to analyze the subsets of NK cells, particularly on day 3 post-cytokine complex treatment. We observed that IL-15SA/IL-15RαSu-Fc significantly promoted the development of "high effector" (CD11b + CD27 hi ) NK cells, peaking on day 3 post cytokine complex treatment. It is interesting to note that the level of high effector NK cells returned to the baseline by day 7, whereas the significant level of "terminal effector" (CD11b + CD27 lo ) NK cells still remained above the baseline (Figure 4A) , indicative of the greater migratory capacity of high effector NK cells for tissue infiltration [21, 22] .
Prior to the NK subset analysis mentioned above, we originally hypothesized that IL-15SA/IL-15RαSu-Fc would not have a significant impact on the per-cell function of NK cells, as nearly all NKs in naive Balb/c mice (day 0) showed an activated phenotype (~80% of CD49b + NKs were CD122 + NKp46 + ) and maintained similar levels of the activated state throughout the in vivo kinetics study of immune cells exposed to IL-15-SA/IL-15Rα ( Figure 4 ). As expected, IL-15SA/IL15RαSu-Fc increased total splenic NK activity ( Figure  5A ). Unexpectedly, the significant increase in per-cell function of NK cells was observed ( Figure 5B ). We found that the effect of ALT-803 on NK and CD8+ T cells in tumor-bearing mice ( Figure 6 ) was very similar to those in tumor-free mice (Figure 2 ). Regulatory T cells and monocytes/monocytic-MDSCs in tumor bearing mice also showed similar results as in tumor-free mice. As seen in tumor-free mice, ALT-803 significantly increased the number of neutrophils/granulocytic MDSCs in tumor bearing mice ( Figure 6 ).
We attribute this enhanced per-cell function to increased development of high effector NK cells induced by IL-15-SA/IL-15RαSu-Fc. This finding also underscores the need for in-depth phenotypic and functional analyses of NK cell subsets. Adding to the potential complexity of these subsets, a cytometry by time of flight (CyTOF) analysis of human NKs revealed that there were 30,000 unique NK cell subsets found in 22 healthy individuals [40] . It has been postulated that this enormous number of unique NK subsets can be categorized on the basis of their ability to protect against different types of pathogens and, perhaps, also tumors [40] [41] [42] .
We used two highly metastatic tumor models to examine the anti-tumor efficacy of IL-15-SA/IL-15RαSu-Fc. First, in the 4T1 breast tumor model, IL-15SA/IL15RαSu-Fc was effective in reducing lung metastases, dependent on CD8 + T as well as NK cells, and increased the median overall survival from 38 to 50 days postsurgical resection of the primary tumor (Figure 7) . In our study, CD8 + T cells and NK cells played a prominent role in inhibiting pulmonary 4T1 metastasis ( Figure 7C and 7D). Because IL-15SA/IL-15RαSu-Fc significantly induces the expansion of high effector NK cells (Figure 4) , which have been shown to express a high level of CXCR3 [21, 22] and exhibit superior migratory capacity [21, 22] , incorporating IL-15SA/IL-15RαSu-Fc into a vaccinebased immunotherapy may synergistically enhance priming and activation of tumor-antigen specific T cells, mediated by this subpopulation of NK cells.
Next, we employed the CT26 pulmonary metastasis model not only to determine the extent to which the antimetastatic property of IL-15SA/IL-15RαSu-Fc could be applied to a different tumor type, but also to combine IL-15SA/IL-15RαSu-Fc with an immune checkpoint therapy using, for example, anti-CTLA-4 or anti-PD-L1 antibodies. The immune checkpoint receptor ligands B7-1 and PD-L1 are upregulated on certain tumors and have been shown to inhibit T cell function by contributing to the tumor's ability to evade the immune system [43] . Thus, checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1 or anti-PD-L1 antibodies can enhance T cell responses by breaking peripheral tolerance and preventing immune exhaustion [43, 44] . Additional combination therapies with immunostimulatory agents such as IL-15SA/IL-15RαSu-Fc, which promotes T cell proliferation and enhances their cytotoxicity, can potentially provide synergistic antitumor responses. In contrast to 4T1 tumor cells, which did not markedly express B7-1 and PD-L1, CT26 tumor cells expressed a low level of PD-L1 but a high level of B7-1 (see Results); hence their practicability for immune checkpoint combination therapy, specifically with anti-CTLA-4. Administration of IL-15SA/IL-15RαSu-Fc and anti-CTLA-4, but not anti-PD-L1, generated a synergistic anti-tumor response in CT26-bearing mice ( Figure 8B ), which is consistent with the observation that the efficacy of checkpoint inhibitors, in particular anti-PD-1 and PD-L1, is dependent on the surface expression of inhibitory ligands on tumor cells [45] [46] [47] . More interestingly, anti-PD-L1, albeit ineffective in combination with IL-15SA/IL-15RαSu-Fc in this tumor model, appeared to further improve survival when administered in conjunction with both IL-15SA/IL15RαSu-Fc and anti-CTLA-4 ( Figure 8C ). We believe that CTLA-4/B7-1 blockade via anti-CTLA-4 induced IFN-γ secretion not only from T cells, but also from NK cells, which have been shown to express CTLA-4 in mediating IFN-γ production [48] . This likely resulted in increased expression of PD-L1 on CT26 tumor cells, rendering anti-PD-L1 efficacious. Our studies combining the IL-15 reagent with anti-CTLA-4 and/or PDL1 reflect our vision that the most effective therapies will be in combination with the emerging checkpoint inhibitors. We feel that increased survival in the CT26 tumor model (and control of macroscopic disease in the 4T1 model) can be further optimized by timing and sequencing of these reagents.
In conclusion, the results shown here support the use of IL-15SA/IL-15RαSu-Fc for anti-metastatic treatment against common non-hematologic tumors such as breast and colon carcinomas. Because IL-15SA/IL-15RαSu-Fc predominantly activated the innate arm of the immune system (Figures 2-4) , a combination strategy involving the reagents that stimulate the adaptive arm of anti-tumor immunity, in particular recombinant vaccines or checkpoint inhibitors demonstrated in this study, may prove to be highly effective in the treatment of metastatic cancers.
MATERIALS AND METHODS
Animals
Female Balb/c mice were housed and maintained in microisolator cages under specific pathogen-free conditions and in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines. All experimental studies were carried out under the approval of the National Institutes of Health (NIH) Intramural Animal Care and Use Committee.
Tumor cells
4T1 murine mammary and CT26 murine colon carcinoma cell lines were purchased from American Type Culture Collection and maintained in the recommended medium.
IL-15SA/IL-15RαSu-Fc (ALT-803) reagent
IL-15SA/IL-15RαSu-Fc (ALT-803) was generated as described previously [11] and kindly provided by Altor BioScience Corporation (Miramar, FL) under a Cooperative Research and Development Agreement (CRADA).
Kinetic analysis of IL-15-SA/IL-15Rα-Fcmediated immune responses
For each day, a group of naïve female Balb/c mice (n=3) was injected only once with IL-15SA/IL15-RαSu-Fc (1 µg in 100 µl, i.p.); their sera and spleens, including those from the control-PBS group (n = 3), were collected on day 7. Mouse sera were characterized for TH 1 and TH 2 cytokines using a cytokine multiplex analysis (Clinical Support Laboratory, NCI-Frederick). Mouse spleens were passed through a 70µM cell strainer and homogenized into a single cell suspension, followed by alkaline lysis of red blood cells, for antibody staining and flow analysis.
Flow cytometry analysis; surface and intracellular marker assays NK cytotoxicity assay
Female Balb/c mice (n = 5-10/group) were given a single injection of IL-15SA/IL-15RαSu-Fc (1 µg in 100 µl, i.p.) or PBS (100 µl i.p.). On day 3, their spleens were harvested and processed as above. Mouse splenocytes were either used as effectors or purified for NK cells using the NK Cell Isolation Kit II (Miltenyi Biotec, San Diego, CA). YAC-1 target cells were labeled with 111 In and co-cultured with bulk splenocytes or purified NK cells at 100:1, 10:1, and 1:1 effector-to-target ratios. For the NKG2D blocking assay, anti-mouse NKG2D (10 µg/ml; R&D Systems, Minneapolis, MN) or isotype control mAb was added to NK cells, incubated at room temperature for 20 min, then 111 In-labeled YAC-1 cells were added. After incubation at 37° C for 4 hours, radioactivity in supernatant was measured using a γ counter (WIZARD 2 ; PerkinElmer, Waltham, MA). Where indicated, NK activity was converted to lytic units (LU), as described by Wunderlich et al. [49] .
T/NK cell depletion study
Female Balb/c mice (n=15/group) were injected with 4T1 mammary tumor cells and given IL-15SA/IL15RαSu-Fc (1 µg in 100 µl, i.p.) or PBS (100 µl i.p.) as above. T cell depletion was started on the day of tumor implantation using a daily dose (100 µg, i.p.) of anti-CD4 (Clone GK1.5) or anti-CD8 (Clone 2.43), purchased from BioXcell (West Lebanon, NH) for first the 3 days and once a week thereafter until harvest of the lungs (days [25] [26] [27] [28] [29] . For NK depletion using anti-Asialo-GM1, it was reported that the greatest reduction of NK cell activity was seen on day 3 after one-shot injection, recovered on day 7, and rose to more than 50% of the original value on day 14 in nude and Balb/c mice [50] . Therefore, the following depletion schedule was used: briefly, 10 µl of anti-Asialo-GM1 (Wako Chemicals USA, Inc., Richmond, VA), diluted 1:5 in PBS, was injected 100 µl i.p. 1 day prior to IL-15SA/IL-15RαSu-Fc administration, then thereafter every 5-6 days until harvest of the lungs (days [25] [26] [27] [28] [29] [30] . The percent depletions of T and NK cells was checked on the day prior to IL-15SA/IL-15RαSu-Fc administration (CD4: 98.6%; CD8: 97.4%; NK: 91.6%) and 4 days after the last injection (CD4: 87.1%; CD8: 77.1%; NK: 33.7%).
4T1 anti-tumor and survival study
Female Balb/c mice (n = 15/group) were injected with 5 x 10 4 4T1 mammary tumor cells. Seven days after implantation, IL-15SA/IL-15RαSu-Fc (1 µg in 100 µl, i.p.) or PBS (100 µl i.p.) was administered. Tumors were measured twice a week. When the tumor volume (L x W 2 /2) reached 1000-1200 mm 3 , mice were euthanized, and their lungs were harvested and dispersed into single cell suspension, which was plated in the presence of 6-thioguanine (Sigma-Aldrich, St. Louis, MO). Twelve days later, cells were fixed with methanol, stained with 0.03% methylene blue, and the number of clonogenic metastatic cells was counted. For the survival study, primary tumors were surgically removed on day 14 post 4T1 implantation, then the survival of IL-15-SA/IL-15Rα-Fc-treated (N=6) or PBS-treated (N=9) mice was examined. Mice where surgery failed to control primary tumor (Dia. > 1.9 cm) after tumor resection were excluded for the survival analysis.
CT26 anti-tumor and survival study
Female Balb/c mice (n = 6-8/group) were injected with 2x 10 5 CT26 tumor cells intravenously (i.v.) on day 0. Treatment began 1 day later. In the rIL-15 treatment group, each mouse received 5 µg of rIL-15 (NCI, lot #: L0810009, Conc: 0.59 mg/ml, DOM: 12/03/08) i.p. daily, five times a week for 2 weeks. Along with rIL-15, animals also received both anti-mouse-PD-L1 antibody (clone 9G2; Biolegend) and anti-CTLA-4 antibody (clone UC10-4F10-11; Altor). In the IL-15SA/IL-15RαSu-Fc treatment group, each mouse received 4 µg of IL-15SA/IL-15RαSu-Fc i.v. twice a week. Along with IL-15-SA/IL-15RαSu-Fc, some mice receive either anti-mouse-PD-L1 antibody, anti-CTLA-4 antibody or both anti-mouse-PD-L1 and anti-CTLA-4 antibodies. The dose and schedule of these antibodies were 100 µg per injection administered twice a week for 2 weeks. Control mice received injections of PBS. Survival was set as an endpoint, and mice were monitored for weight changes thrice a week until the termination of the study.
Statistical analysis
Unless specified, results of tests of significance are indicated as p values derived from a two-tailed Student's t test. All p values were derived at 95% using GraphPad Prism 6 statistical software for PCs (GraphPad Software, Inc., La Jolla, CA).
